Tag Directory / FDA     showing 1–1 of 1   RSS

for: Saturday, June 20, 2026



FDA approves Welireg with pembrolizumab for renal cell carcinoma

medicalxpress - The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma in adults with a clear ce…

AI Summary: The FDA cleared Welireg (belzutifan) in combination with pembrolizumab for adjuvant treatment of renal cell carcinoma at high risk of recurrence after surgery. The approval expands belzutifan’s indications, offering a new post‑nephrectomy option intended to lower recurrence risk and reflecting regulators’ willingness to endorse targeted therapy combinations in kidney cancer.

Katy Beckermann: Patients Hear What We Say Through the Lens of Hope

21 days / oncodaily

FDA approves Welireg with pembrolizumab for renal cell carcinoma

21 days / medicalxpress

FDA Approves Belzutifan Plus Pembrolizumab for Adjuvant RCC

23 days / oncodaily

Enrique Grande: FDA Approves Adjuvant Belzutifan + Pembrolizumab for RCC at High Risk of Reccurence

24 days / oncodaily

FDA expands use of kidney cancer drug belzutifan

25 days / medicalxpress



Back to Top


FDA Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Hospital Operations, Supply Chain, Diagnostics, Drug Development and look for the RSS link.

Back to Top
↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.